Dr. Patel on Choosing a Chemoimmunotherapy Treatment in NSCLC
Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.
Dr. Patel on the Role of CTLA-4 Inhibitors in NSCLC
Manish Patel, DO, discusses the role of CTLA-4 inhibitors in non–small cell lung cancer.
Dr. Patel on the Safety Profile of Entrectinib in NTRK+ Solid Tumors
Manish R. Patel, DO, discusses the safety profile of entrectinib in NTRK fusion–positive solid tumors.
Dr. Patel on the Role of Entrectinib in Gastrointestinal Malignancies
Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.
Dr. Patel on Choosing Immunotherapy Drugs for NSCLC
Manish R. Patel, DO, discusses choosing immunotherapy drugs for patients with non–small cell lung cancer.
Dr. Patel on Ongoing Immunotherapy Research for NSCLC
Manish R. Patel, DO, discusses current questions and research regarding immunotherapy in non–small cell lung cancer.
Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.